Amgen Inc. (AMGN) Given a $180.00 Price Target at UBS AG
UBS AG set a $180.00 price objective on Amgen Inc. (NASDAQ:AMGN) in a research note released on Wednesday morning, www.benzinga.com reports. The brokerage currently has a hold rating on the medical research company’s stock.
A number of other analysts have also recently weighed in on the stock. Oppenheimer Holdings, Inc. set a $189.00 price objective on shares of Amgen and gave the stock a buy rating in a research note on Tuesday, May 9th. Mizuho set a $195.00 price objective on shares of Amgen and gave the stock a buy rating in a research note on Saturday, May 6th. Cowen and Company restated a buy rating and issued a $209.00 price objective on shares of Amgen in a research note on Thursday, April 27th. Vetr cut shares of Amgen from a strong-buy rating to a buy rating and set a $178.82 price objective for the company. in a research note on Monday, April 3rd. Finally, BMO Capital Markets restated a buy rating and issued a $198.00 price objective (down from $200.00) on shares of Amgen in a research note on Monday, May 22nd. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, eleven have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Amgen presently has an average rating of Buy and an average target price of $186.64.
Amgen (NASDAQ AMGN) traded up 1.39% during midday trading on Wednesday, reaching $174.54. 2,463,475 shares of the company were exchanged. The firm has a market cap of $127.36 billion, a P/E ratio of 15.90 and a beta of 1.36. Amgen has a one year low of $133.64 and a one year high of $184.21. The firm’s 50-day moving average is $172.48 and its 200-day moving average is $166.30.
Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The company’s revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the company earned $2.84 earnings per share. On average, equities analysts expect that Amgen will post $12.57 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Amgen Inc. (AMGN) Given a $180.00 Price Target at UBS AG” was originally posted by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/amgen-inc-amgn-given-a-180-00-price-target-at-ubs-ag/1462852.html.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be issued a $1.15 dividend. This represents a $4.60 annualized dividend and a dividend yield of 2.64%. Amgen’s payout ratio is 41.93%.
In other news, SVP Cynthia M. Patton sold 2,922 shares of the company’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total value of $451,156.80. Following the sale, the senior vice president now owns 24,214 shares of the company’s stock, valued at approximately $3,738,641.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.20% of the stock is currently owned by corporate insiders.
Several large investors have recently bought and sold shares of the company. Camelot Portfolios LLC purchased a new stake in Amgen during the first quarter valued at $1,429,000. Private Asset Management Inc. raised its stake in Amgen by 117.8% in the first quarter. Private Asset Management Inc. now owns 3,591 shares of the medical research company’s stock valued at $589,000 after buying an additional 1,942 shares during the last quarter. Cadence Bank NA raised its stake in Amgen by 6.2% in the first quarter. Cadence Bank NA now owns 3,376 shares of the medical research company’s stock valued at $554,000 after buying an additional 197 shares during the last quarter. Stillwater Capital Advisors LLC purchased a new stake in Amgen during the first quarter valued at $202,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new stake in Amgen during the fourth quarter valued at $275,209,000. 78.87% of the stock is currently owned by institutional investors and hedge funds.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.